Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07104091 in Advanced Breast, Ovarian, and Lung Cancers
NCT04553133Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of tegtociclib in small cell lung cancer (SCLC), ovarian cancer, breast cancer and 1 more (7 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities at 28 days, Treatment-emergent adverse events up to 2 years and 4 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
tegtociclib
03
Conditions
small cell lung cancer (SCLC)ovarian cancerbreast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04553133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553133.